Organoids and organs-on-a-chip as new approach methodologies at the convergence of cell biology and bioengineering

The rapid growth of new approach methodologies (NAMs), including organoids and organs-on-a-chip (OOCs), has revealed a need for interdisciplinary dialogue between cell biologists and bioengineers to develop human models that can best complement therapeutic development. Stem cell-derived and bioengineered human tissue models are redefining how we understand human physiology and pathophysiology, offering control that traditional preclinical models cannot provide. By recapitulating complex tissue microenvironments, multi-organ interactions, and patient-specific biology, these systems are bridging long-standing gaps in the drug development and clinical application pipelines. Here, we synthesize advances in organoids, OOCs, and other bioengineered technologies for translational medicine to identify remaining gaps, including challenges in reproducibility, validation, and regulatory acceptance. Emerging opportunities at the intersection of synthetic biology, multi-omics, machine learning, and genetic engineering are positioning NAMs not merely as improved experimental tools but as foundational platforms for accelerating therapeutic discovery and enabling personalized medicine at scale.